We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+40.65%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$3.13B
AUM Growth
+$681M
Cap. Flow
-$365M
Cap. Flow %
-11.64%
Top 10 Hldgs %
43.55%
Holding
107
New
15
Increased
23
Reduced
25
Closed
31

Top Buys

Rank Stock Value
1
AHCO icon
AdaptHealth
AHCO
+$171M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$55.9M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$37.8M
4
KRRO icon
Korro Bio
KRRO
+$22.1M
5
ARDX icon
Ardelyx
ARDX
+$21.9M

Top Sells

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$57.9M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$52.7M
3
CHRS icon
Coherus Oncology
CHRS
+$31.2M
4
IMMU
Immunomedics Inc
IMMU
+$26.3M
5
DFBHU
DFB Healthcare Acquisitions Corp. Unit
DFBHU
+$25.8M

Sector Composition

Rank Sector Weight
1 Healthcare 77.62%
2 Financials 0.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CSTL icon
76
Castle Biosciences
CSTL
$733M
– –
-92,477
Closed -$1.67M
HYPD
77
Hyperion DeFi Inc
HYPD
$41.5M
– –
-2,463
Closed -$729K
GH icon
78
Guardant Health
GH
$20.7B
– –
-126,000
Closed -$8.04M
LKFT
79
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
– –
-101,010
Closed -$15.4M
IDYA icon
80
IDEAYA Biosciences
IDYA
$3.47B
– –
-422,974
Closed -$3.81M
IGMS
81
DELISTED
IGM Biosciences
IGMS
– –
-250,000
Closed -$4.44M
KALV
82
DELISTED
KalVista Pharmaceuticals
KALV
– –
-890,668
Closed -$10.3M
KNSA icon
83
Kiniksa Pharmaceuticals
KNSA
$4.92B
– –
-1,274,086
Closed -$10.8M
PTCT icon
84
PTC Therapeutics
PTCT
$6.52B
– –
-471,000
Closed -$15.9M
SYBX
85
DELISTED
Synlogic
SYBX
– –
-73,843
Closed -$2.54M
SYRE icon
86
Spyre Therapeutics
SYRE
$8.7B
– –
-20,002
Closed -$3.85M
VYNE icon
87
VYNE Therapeutics
VYNE
$25.4M
– –
-1,384
Closed -$446K
WVE icon
88
Wave Life Sciences
WVE
$1.12B
– –
-807,727
Closed -$16.6M
ALIM
89
DELISTED
Alimera Sciences
ALIM
– –
-470,840
Closed -$4M
MOR
90
DELISTED
MorphoSys AG American Depositary Shares
MOR
– –
-124,701
Closed -$3.43M
HARP
91
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
– –
-26,450
Closed -$3.61M
VRAY
92
DELISTED
ViewRay, Inc.
VRAY
– –
-378,623
Closed -$1.1M
PRVB
93
DELISTED
Provention Bio, Inc. Common Stock
PRVB
– –
-725,000
Closed -$4.95M
AGRX
94
DELISTED
Agile Therapeutics
AGRX
– –
-796
Closed -$1.89M
ABMD
95
DELISTED
Abiomed Inc
ABMD
– –
-27,600
Closed -$4.91M
AIMT
96
DELISTED
Aimmune Therapeutics
AIMT
– –
-339,480
Closed -$7.11M
DPLO
97
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
– –
-2,996,328
Closed -$14.7M
MDCO
98
PUT
DELISTED
Medicines Co
MDCO
– –
-100,000
Closed -$5M
DFBHU
99
DELISTED
DFB Healthcare Acquisitions Corp. Unit
DFBHU
– –
-2,500,000
Closed -$25.8M
BDSI
100
DELISTED
BioDelivery Sciences International, Inc.
BDSI
– –
-816,096
Closed -$3.44M
1 2 3
4

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q4 2019 Portfolio in Review

As of Q4 2019, Deerfield Management held 107 positions worth $3.13B, up 28% from $2.45B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Deerfield Management withdrew a net $365M in Q4 2019, closing 31 positions and reducing 25 holdings. Its most notable exit was Coherus Oncology, an estimated $31.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 71% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in AdaptHealth worth $189M.

  • Deerfield Management's largest Q4 2019 buy was AdaptHealth: 17,199,888 shares worth $189M.
  • Deerfield Management added most to Tandem Diabetes Care in Q4 2019, an estimated $55.9M increase.
  • Deerfield Management's biggest Q4 2019 reduction was Aerie Pharmaceuticals, cutting an estimated $57.9M.
  • Deerfield Management fully exited Coherus Oncology in Q4 2019, selling an estimated $31.2M.
  • Deerfield Management's ten largest holdings make up 44% of its $3.13B portfolio in Q4 2019.
  • Deerfield Management opened 15 new positions and closed 31 in Q4 2019.
  • Deerfield Management's portfolio value rose 28% quarter-over-quarter to $3.13B.

Based on Deerfield Management's 13F filing for Q4 2019, filed 14 Feb 2020.